Mounjaro vs Ozempic

The first thing to get straight: these are the diabetes brands

Mounjaro and Ozempic are two of the most-searched drug names in America, and a huge share of that search traffic is people asking which one to take for weight loss. So the most useful thing this page can do up front is correct the framing: both Mounjaro and Ozempic are FDA-approved only for type 2 diabetes. Neither is approved for weight loss at all.

They are the diabetes brands of two different molecules. Mounjaro is the brand name for tirzepatide, made by Eli Lilly. Ozempic is the brand name for semaglutide, made by Novo Nordisk. Each molecule also has a separate, differently-named brand approved specifically for weight management: tirzepatide is sold as Zepbound for obesity (and obstructive sleep apnea), and semaglutide is sold as Wegovy for weight management.

That distinction is not a technicality — it changes the whole comparison. If you have type 2 diabetes, Mounjaro vs Ozempic is genuinely your decision, and the rest of this page is for you. If you do not have diabetes and you are comparing these two for weight loss, you are comparing the wrong two drugs: the right comparison is Wegovy vs Zepbound, and trying to get Mounjaro or Ozempic prescribed off-label for weight loss usually means your insurance will not cover it.

Note: “Mounjaro vs Ozempic” and “tirzepatide vs semaglutide” are not the same question. This page is the brand-level, diabetes-focused view. For the deeper molecule science — mechanism, the obesity head-to-head, heart-vs-sleep-apnea trade-offs — see semaglutide vs tirzepatide.

The head-to-head diabetes trial

Most drug comparisons rely on indirect evidence, because the two drugs were never tested against each other. Mounjaro and Ozempic are a rare exception: they were compared directly in people with type 2 diabetes.

The trial was SURPASS-2, published in the New England Journal of Medicine in 2021. It randomized nearly 1,900 adults with type 2 diabetes (already on metformin) to tirzepatide or to semaglutide, and ran for 40 weeks. The result was clear: tirzepatide lowered A1c and body weight more than semaglutide at every dose tested. One illustrative figure — about half of the people on the highest tirzepatide dose got their A1c below the threshold seen in people without diabetes, roughly double the proportion on semaglutide.

Two honest caveats keep that result in proportion. First, SURPASS-2 compared tirzepatide against the 1 mg dose of semaglutide; a higher 2 mg Ozempic dose has since become available, which narrows (but does not erase) the gap in everyday practice. Second, trial participants were a relatively uniform, treatment-naïve group, so real-world differences tend to be smaller than the trial’s. Large U.S. real-world analyses through 2025 have echoed the same direction — tirzepatide ahead on average for blood sugar and weight — just by a more modest margin.

For a diabetes drug, this is the primary axis: tirzepatide’s dual mechanism gives it an edge on the two outcomes diabetics are usually chasing, glucose control and weight. But blood sugar is not the only thing a modern diabetes drug is judged on — and on the other axes, the picture flips.

Where Ozempic still leads: heart and kidney protection

For someone with type 2 diabetes, the biggest long-term threats are cardiovascular and kidney disease. This is where the label — what each drug is officially approved to do — matters, because it reflects which outcomes have been formally proven and reviewed.

Ozempic is the most broadly indicated GLP-1 drug in its class. Beyond improving blood sugar, semaglutide carries an FDA-approved indication to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease, based on the SUSTAIN-6 outcomes trial. Then in January 2025, the FDA added a chronic kidney disease indication, on the strength of the FLOW trial, which found roughly a 24% reduction in the risk of kidney-disease progression, kidney failure and cardiovascular death. That makes Ozempic the only GLP-1 receptor agonist approved to slow kidney disease — a genuinely meaningful distinction for the large overlap of patients who have both diabetes and CKD.

Mounjaro, until recently, simply had no cardiovascular or kidney outcomes data of its own. That changed in late 2025.

Mounjaro’s heart evidence: strong, but the label hasn’t caught up

SURPASS-CVOT, tirzepatide’s first dedicated cardiovascular outcomes trial, reported topline in mid-2025 and was published in the New England Journal of Medicine in December 2025. It enrolled more than 13,000 adults with type 2 diabetes and established heart disease and ran about 4.5 years — and, importantly, it did not compare tirzepatide against placebo. It compared it head-to-head against dulaglutide (Trulicity), an older GLP-1 that already has proven cardiovascular benefit. Designing the trial this way was a high bar: the comparator was active, effective therapy, not a sugar pill.

Tirzepatide met its primary goal of non-inferiority to dulaglutide for major cardiovascular events, with roughly an 8% lower rate of heart attack, stroke or cardiovascular death, plus reductions in deaths from any cause and signals of kidney benefit. In plain terms: it preserved the heart protection of an established GLP-1 while adding more on weight, blood sugar, and kidney measures.

Two pieces of context keep this honest. Some investors and analysts were underwhelmed because the trial showed non-inferiority rather than outright superiority over dulaglutide — the dual mechanism had raised hopes of a clear win. And, crucially, as of mid-2026 Mounjaro does not yet carry a formal FDA cardiovascular indication on its label. Lilly submitted the data to regulators and an expanded indication is widely expected, but it has not been granted. The evidence is now genuinely strong; the regulatory paperwork is still in motion.

So the heart-and-kidney comparison in 2026 sits in an unusual place. The underlying data for the two molecules are closer than they have ever been. But on paper, today, Ozempic holds approved indications for cardiovascular risk reduction and kidney protection that Mounjaro does not. If you are choosing a diabetes drug specifically because you already have heart or kidney disease, that current label difference is a real factor — even as the gap in the evidence narrows.

Side effects: more alike than different

Both drugs share the same broad safety story, because they belong to the same broad class. The most common side effects are gastrointestinal — nausea, diarrhea, constipation and vomiting — and they are dose-related, usually worst during dose increases, and tend to ease as the body adjusts. In the SURPASS-2 head-to-head data, the overall rates were broadly comparable between the two.

There is an open scientific question about whether tirzepatide’s GIP component changes tolerability, and the data are genuinely mixed — some analyses rank it slightly higher for GI effects, others find the per-patient profile similar despite larger weight loss. The practical takeaway is that how quickly the dose is escalated tends to matter more than which molecule you are on. Both also carry the same boxed warning about thyroid C-cell tumors seen in rodents (not established in humans) and the same contraindication for people with a personal or family history of medullary thyroid cancer or MEN2. For a fuller treatment, see the dedicated side-effect pages for each molecule rather than relying on a comparison summary.

Cost and coverage: the cleanest part of the comparison

Here is where the diabetes brands differ most from their weight-loss cousins. Because Mounjaro and Ozempic are approved for diabetes, they are broadly covered — by most commercial plans (typically with prior authorization) and, unlike weight-loss drugs, by Medicare Part D, which by law cannot cover a drug used purely for weight loss but does cover diabetes treatment. That makes this the most coverage-friendly of all the GLP-1 comparisons.

List prices are similar — both land in the rough neighborhood of $1,000–1,100 a month before insurance — and both manufacturers now offer self-pay and savings-card routes tied to the diabetes indication. What you actually pay is driven almost entirely by your specific plan and formulary, not by which brand you pick. The one consistent trap: the moment either drug is prescribed off-label for weight loss instead of diabetes, that favorable coverage tends to evaporate.

This page keeps pricing deliberately light because it varies so much by plan; for the route-by-route detail, see Mounjaro cost in the US and Ozempic cost in the US, and for how prior authorization and Part D actually work, GLP-1 insurance coverage.

So which one?

There is no single winner, because the two drugs are strong on different things — and the right answer depends on the patient in front of the prescriber, not on a headline.

If you have type 2 diabetes and the priority is maximum blood-sugar and weight improvement, tirzepatide (Mounjaro) has the head-to-head edge from SURPASS-2 and the real-world data that followed.

If you have type 2 diabetes plus established cardiovascular disease or chronic kidney disease, semaglutide (Ozempic) currently holds the broader, FDA-approved label for exactly those outcomes — including the only kidney-disease indication in the class — even though Mounjaro’s own outcomes evidence has now caught up substantially and its label may expand.

If tolerability, dosing convenience, or what your plan will actually cover is the deciding factor, those frequently outweigh a few percentage points of efficacy, and they are individual.

And if you do not have diabetes at all: this is not your comparison. The weight-management decision is Wegovy vs Zepbound, and the molecule-level science is in semaglutide vs tirzepatide. The honest bottom line for diabetes is that both are excellent, genuinely disease-modifying drugs — the choice is a clinical one made with a prescriber who can weigh your A1c, your heart and kidneys, your tolerance, and your coverage together.

This article is educational and current as of its last-updated date; drug indications, approvals and coverage are changing quickly in 2026 and may have moved since. It is not medical advice, and treatment decisions should be made with a licensed clinician.